Roivant Sciences Ltd. sold (to issuer) $44.8M of ABUS

Arbutus Biopharma (ABUS) can now advance U.S. clinical trials for AB-101 after the FDA lifted its clinical hold. The oral PD-L1 inhibitor completed a Phase 1a/1b trial, showing good tolerability and some efficacy in cHBV patients. The company is evaluating next steps for development.

Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa

Arbutus Biopharma (ABUS) announced the FDA lifted its clinical hold on AB-101, an oral PD-L1 inhibitor for chronic HBV, allowing further U.S. clinical development. The company is assessing next steps. According to Arbutus, this enables additional U.S. clinical trials for AB-101.

Arbutus Biopharma (Nasdaq: ABUS) announced the FDA lifted a clinical hold on its experimental oral hepatitis B drug, AB-101. The company plans to continue development. AB-101 showed promising results in a Phase 1a/1b trial, with evidence of high receptor occupancy and hepatitis B surface antigen decline in some patients.

Arbutus Biopharma accepted 46M shares at $5.00 per share in its tender offer, which expired on September 29, 2026. The offer aimed to purchase up to $230M of shares. Roivant Sciences tendered 8.97M shares, receiving $44.84M, and now owns 19.5% of outstanding shares.

Arbutus Biopharma (ABUS) completed a $230M share buyback, retiring 23% of its shares at $5 each. The tender offer was oversubscribed, with 46M shares accepted and 153.3M remaining. Roivant Sciences, holding 19.5%, participated proportionately.